Filing Flows › Lemaitre Vascular (LMAT) › Guidance & outlook
Lemaitre Vascular (LMAT) guidance and outlook
Lemaitre Vascular (LMAT) raised some and lowered other parts of its guidance on Nov 4, 2026: EPS +18% for FY2026; Gross margin 72.1% for Q4 2026; Gross margin 72.1% for FY2026; EPS $0.25 for FY2026. Lemaitre Vascular's 10-Q filed Nov 5, 2026 makes 17 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +11% | new |
| EPS | FY2026 | +18% | new |
| Gross margin | Q4 2026 | 72.1% | raised |
| Gross margin | FY2026 | 72.1% | new |
| EPS | FY2026 | $0.25 | new |
| Revenue | the quarter ending Dec 31, 2025 | +11% | lowered |
| Revenue | the year ending Dec 31, 2025 | $276K | reaffirmed |
| Revenue | the year ending Dec 31, 2025 | +11% | reaffirmed |
| Operating income | the year ending Dec 31, 2025 | +17% | lowered |
| EPS | the year ending Dec 31, 2025 | $2.80 | raised |
| EPS | the year ending Dec 31, 2025 | +18% | lowered |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We estimate that the annual worldwide market for peripheral vascular devices exceeds $9 billion, within which we estimate that the market for our products is approximately $1 billion.
- We have used acquisitions as a primary means of further penetrating the peripheral vascular device market, and we expect to continue this strategy in the future.
- There can be no assurance that we will be able to do so in the future.
- We expect to begin selling direct-to-hospitals in Poland starting January 2027.
- We expect these plant consolidations and manufacturing transfers will result in improved control over production quality as well as reduced costs.
- We intend to continue rolling out the new system in our other international locations on a staged basis.
- We expect foreign currencies will represent a significant percentage of future sales.
- In such cases we will record more revenue in U.S. dollars than we would have if the exchange rate had not changed.
- ended September 30, 2026, we estimate that the effects of changes in foreign exchange rates increased our reported sales by approximately $2.0 million, as compared to rates in effect for the nine months ended September 30, 2025.
- We estimate that the stronger U.S. dollar decreased net sales by $0.4 million during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025.
- We estimate that the weaker U.S. dollar increased net sales by $2.0 million during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025.
- We monitor the mix of profitability by tax jurisdiction and adjust our annual expected rate on a quarterly basis as needed.
Lemaitre Vascular's latest quarter
Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%, net earnings $15.0M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Lemaitre Vascular raise or lower its guidance?
Lemaitre Vascular (LMAT) raised some and lowered other parts of its guidance on Nov 4, 2026: EPS +18% for FY2026; Gross margin 72.1% for Q4 2026; Gross margin 72.1% for FY2026; EPS $0.25 for FY2026.
What does Lemaitre Vascular expect?
We estimate that the annual worldwide market for peripheral vascular devices exceeds $9 billion, within which we estimate that the market for our products is approximately $1 billion. We have used acquisitions as a primary means of further penetrating the peripheral vascular device market, and we expect to continue this strategy in the future. There can be no assurance that we will be able to do so in the future.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.